OFI Invest Asset Management Acquires 470,804 Shares of Gilead Sciences, Inc. $GILD

OFI Invest Asset Management grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 124.4% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 849,277 shares of the biopharmaceutical company’s stock after buying an additional 470,804 shares during the quarter. Gilead Sciences accounts for about 1.3% of OFI Invest Asset Management’s investment portfolio, making the stock its 14th biggest position. OFI Invest Asset Management owned 0.07% of Gilead Sciences worth $104,240,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Corundum Trust Company INC purchased a new stake in shares of Gilead Sciences in the third quarter valued at approximately $26,000. Financial Consulate Inc. boosted its holdings in shares of Gilead Sciences by 85.8% in the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 109 shares during the period. MTM Investment Management LLC boosted its holdings in shares of Gilead Sciences by 176.0% in the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 176 shares during the period. Board of the Pension Protection Fund purchased a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $37,000. Finally, Millstone Evans Group LLC boosted its holdings in shares of Gilead Sciences by 58.7% in the third quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 118 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD opened at $141.54 on Thursday. Gilead Sciences, Inc. has a 12 month low of $93.37 and a 12 month high of $157.29. The stock has a fifty day moving average price of $145.13 and a 200-day moving average price of $130.09. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. The firm has a market cap of $175.68 billion, a PE ratio of 20.91, a P/E/G ratio of 1.83 and a beta of 0.39.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The firm had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. During the same quarter in the prior year, the business posted $1.90 EPS. The business’s revenue for the quarter was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 30th. Stockholders of record on Friday, March 13th were issued a dividend of $0.82 per share. The ex-dividend date was Friday, March 13th. This represents a $3.28 annualized dividend and a dividend yield of 2.3%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s dividend payout ratio (DPR) is currently 48.45%.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead agreed to buy Tubulis for up to $5.0B (≈$3.15B upfront + up to $1.85B in milestones), adding an ADC platform and clinical assets (TUB‑040, TUB‑030) to bolster its oncology pipeline — a clear strategic push to diversify into higher-growth cancer therapies. Gilead to Acquire Tubulis (BusinessWire)
• Positive Sentiment: Several sell‑side analysts reiterated or kept bullish views after the M&A wave: Needham and Bernstein expressed constructive views (Needham kept a Buy with a $170 target), signaling investor interest in the deal’s long‑term upside to Gilead’s oncology franchise. Needham: Buy on Tubulis (TipRanks)
• Positive Sentiment: Underlying fundamentals remain solid: Gilead has a recent history of earnings beats and set FY‑2026 EPS guidance (8.45–8.85), which supports valuation while the company reinvests in growth areas. (Earnings/guidance referenced from recent filings and reports.)
• Neutral Sentiment: RBC raised its price target (from $118 to $123) but kept a “sector perform” rating — the new target still sits below current levels, reflecting cautious upside in the bank’s view despite the strategic rationale. RBC adjusts price target on Gilead (MarketScreener)
• Neutral Sentiment: Market headlines note the stock has risen but still slightly underperformed broader indexes over the short term — momentum is positive but not yet broad‑based. Gilead stock rises but underperforms (MarketWatch)
• Negative Sentiment: Some analysts caution on execution and integration risk from a flurry of acquisitions — Goldman Sachs kept a Hold, citing execution risk and the potential for near‑term distraction or cost pressure as Gilead assimilates multiple deals. Goldman Sachs Hold on Gilead (TipRanks)
• Negative Sentiment: The $5B deal includes sizable contingent payments and upfront cash outlays; investors focused on near‑term cash flow, margin impact, or dilution from additional M&A may view the transaction as a risk until assets advance clinically. Gilead to acquire Tubulis (Reuters)

Insiders Place Their Bets

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction on Friday, February 27th. The stock was sold at an average price of $144.79, for a total value of $1,447,900.00. Following the transaction, the chief executive officer directly owned 642,308 shares of the company’s stock, valued at $92,999,775.32. This represents a 1.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $144.23, for a total value of $432,690.00. Following the completion of the transaction, the insider directly owned 131,779 shares in the company, valued at approximately $19,006,485.17. The trade was a 2.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 299,280 shares of company stock worth $42,820,550. 0.27% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of brokerages recently issued reports on GILD. Truist Financial boosted their price target on Gilead Sciences from $145.00 to $152.00 and gave the company a “buy” rating in a report on Wednesday, February 11th. Bank of America set a $162.00 price target on Gilead Sciences and gave the company a “buy” rating in a report on Wednesday, February 11th. Daiwa Securities Group upped their target price on Gilead Sciences from $129.00 to $161.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. Mizuho upped their target price on Gilead Sciences from $140.00 to $170.00 and gave the stock an “outperform” rating in a report on Wednesday, February 18th. Finally, Royal Bank Of Canada upped their target price on Gilead Sciences from $118.00 to $123.00 and gave the stock a “sector perform” rating in a report on Tuesday. Twenty-four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $157.81.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.